• Home
  • > Media & Investors
  • > Media Relations
  • > Press Releases
  • > Daiichi Sankyo and Maruishi Pharmaceutical Launch Analgesic for General Anaesthesia Remifentanil Intravenous Injection 2mg and 5mg “Daiichi Sankyo”

For Immediate Release

2016.12.09

Daiichi Sankyo Co., Ltd.
Maruishi Pharmaceutical Co., Ltd.

Daiichi Sankyo and Maruishi Pharmaceutical Launch Analgesic for General Anaesthesia Remifentanil Intravenous Injection 2mg and 5mg “Daiichi Sankyo”

Tokyo, Japan (December 9, 2016)-Daiichi Sankyo Co., Ltd. (headquarters: Chuo-ku, Tokyo; hereinafter referred to as “Daiichi Sankyo”; Representative Director, President and CEO: Joji Nakayama) and Maruishi Pharmaceutical Co., Ltd. (headquarters: Tsurumi-ku, Osaka; hereinafter referred to as “Maruishi Pharmaceutical”; President: Keiichi Inoue) are pleased to announce today that they have launched a generic version of the analgesic for general anaesthesia Remifentanil Intravenous Injection 2mg and 5mg “Daiichi Sankyo” (date of approval: February 15, 2016; date of listing in the NHI reimbursement price list in Japan: December 9, 2016).

 

Remifentanil injection is an ultra-short acting opioid analgesic characterized by its potent analgesic action together with superior ability to regulate pain, and is widely used for general anaesthesia.

 

Maruishi Pharmaceutical will manufacture Remifentanil Intravenous Injection 2mg and 5mg “Daiichi Sankyo,” while Daiichi Sankyo will handle marketing. Both companies will jointly conduct promotional activities.

  

Product name

Original brand name

Therapeutic category

Remifentanil Intravenous Injection 2mg “Daiichi Sankyo”

Remifentanil Intravenous Injection 5mg “Daiichi Sankyo”

Ultiva® Intravenous 2mg

Ultiva® Intravenous 5mg

Analgesic for general anaesthesia

 

Inquiries

Daiichi Sankyo Co., Ltd.

Corporate Communications Department

Telephone:  +81-3-6225-1126